Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways-Science-Chemical Encyclopedia-lookchem

Iguratimod (cas 123663-49-0) (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways
Add time:08/08/2019 Source:sciencedirect.com

IntroductionIguratimod (cas 123663-49-0) (T-614) has been confirmed as a highly efficacious and safe novel disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis therapy in China and Japan due to its potent anti-inflammation effect. Here, we investigate the effects of Iguratimod on osteoclast differentiation, migration and function.

We also recommend Trading Suppliers and Manufacturers of Iguratimod (cas 123663-49-0). Pls Click Website Link as below: cas 123663-49-0 suppliers

Prev:Iguratimod (cas 123663-49-0) ameliorates inflammatory responses by modulating the Th17/Treg paradigm in dextran sulphate sodium-induced murine colitis
Next: Isolation of 11-oxotetrodotoxin (cas 123665-88-3) from the puffer arothron nigropunctatus)

Click to view details

Encyclopedia